Skip to main content
. Author manuscript; available in PMC: 2022 Feb 6.
Published in final edited form as: Nat Med. 2021 Feb 18;27(3):504–514. doi: 10.1038/s41591-020-01224-2

Extended Data Fig. 9. Association between fecal microbiome diversity and tumor TCR clonality and richness.

Extended Data Fig. 9.

a,c, Heatmaps showing pretherapy taxonomic abundances at various levels in nivolumab (n = 10) and nivolumab plus ipilimumab (n = 9) arms and posttherapy tumor TCR clonality (a) and richness (c). b,d, The relationships between the microbiome and TCR clonality (b) and richness (d) were conducted using the linear regression model. Spearman correlation test (two-sided) was used to calculate the rho and P values. Here, the unadjusted P value cutoff of 0.05 was used.